The Association Between Patient-Reported Self-Management Behavior, Intermediate Clinical Outcomes, and Mortality in Patients With Type 2 Diabetes: Results From the KORA-A Study
- Michael Laxy1,2⇑,
- Andreas Mielck1,
- Matthias Hunger1,
- Michaela Schunk1,
- Christa Meisinger3,
- Ina-Maria Rückert3,
- Wolfgang Rathmann4 and
- Rolf Holle1,2
- 1Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Health Economics and Health Care Management, Neuherberg, Germany
- 2German Center for Diabetes Research (DZD), Germany
- 3Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Epidemiology II, Neuherberg, Germany
- 4German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Institute of Biometrics and Epidemiology, Düsseldorf, Germany
- Corresponding author: Michael Laxy, .
OBJECTIVE Little is known about the impact of diabetes self-management behavior (SMB) on long-term outcomes. We aimed to examine the association among patient-reported SMB, intermediate clinical outcomes, and mortality in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS Data were collected from 340 patients with type 2 diabetes of the KORA-A study (1997/1998) who were recruited from two previous population-based surveys (n = 161) and a myocardial infarction registry (n = 179) in southern Germany. Based on previous methodological work, a high level of SMB was defined as being compliant with at least four of six different self-care dimensions, comprising physical exercise, foot care, blood glucose self-monitoring, weight monitoring, having a diet plan, and keeping a diabetes diary. The vital status of the participants was observed until 2009. Multivariable linear, logistic, and Cox regression models were applied to assess the association with intermediate clinical outcomes at baseline and to predict mortality over the follow-up period, adjusted for sociodemographic, behavioral, and disease-related factors.
RESULTS In the cross-sectional perspective, a high level of SMB was weakly associated with a lower glycated hemoglobin A1c level (−0.44% [−4.8 mmol/mol] [95% CI −0.88–0.00]), but not with low-density lipoprotein cholesterol, systolic blood pressure, or the presence of microalbuminuria, peripheral arterial disease, or polyneuropathy. During a mean follow-up time of 11.6 years, 189 patients died. SMB was a preventive factor for all-cause (hazard ratio 0.61 [95% CI 0.40–0.91]) and cardiovascular mortality (0.65 [95% CI 0.41–1.03]).
CONCLUSIONS Although measuring SMB is difficult and the used operationalization might be limited, our results give some indication that a high level of SMB is associated with prolonged life expectancy in patients with type 2 diabetes and highlight the potential impact of the patients’ active contribution on the long-term trajectory of the disease. We assume that the used proxy for SMB is associated with unmeasured, but important, dimensions of health behavior.
- Received October 30, 2013.
- Accepted January 31, 2014.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.